Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Medical System Network Co., Ltd. operates primarily in the pharmaceutical sector, focusing on the development and distribution of innovative medical therapies and technologies. The company benefits from a strong presence in Asia, particularly in Japan and China, and has a diverse product portfolio that includes oncology and cardiovascular treatments, which are critical growth areas in the healthcare market.
Medical System Network generates revenue primarily through the sale of patented pharmaceuticals, leveraging its strong R&D capabilities to bring innovative products to market. The company has significant pricing power due to its proprietary drugs, which often face limited competition, particularly in oncology. Its established relationships with healthcare providers in Asia enhance its distribution efficiency.
Regulatory approvals for new drugs, particularly in oncology
Market share changes in key therapeutic areas like cardiovascular treatments
Partnership announcements for drug development or distribution
Changes in pricing regulations in major markets such as Japan and China
Regulatory changes that could impact drug pricing and approval processes
Technological advancements that could render current therapies obsolete
Increased competition from generic drug manufacturers
Emerging biotech firms with innovative therapies
High debt levels could lead to liquidity issues if cash flows do not improve
Negative free cash flow of $5.9B raises concerns about financial sustainability
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by broader economic conditions.
Interest rates impact the company's financing costs, especially given its high debt-to-equity ratio of 2.18, which may affect its ability to invest in R&D and expand operations.
high - The company's significant debt levels make it sensitive to credit market conditions, affecting its refinancing capabilities and operational flexibility.
value - The low price-to-sales ratio of 0.1x may attract value investors looking for turnaround opportunities.
high - The stock has shown significant volatility, with a 1-year return of -2.7% and a 6-month return of -11.2%.
